Please login to the form below

Not currently logged in
Email:
Password:

drug pricing

This page shows the latest drug pricing news and features for those working in and with pharma, biotech and healthcare.

J&J earnings top expectations, but feels the squeeze in US

J&J earnings top expectations, but feels the squeeze in US

J&J chalked up the sales decline to a competitive US market, thrown into turmoil  last year by Trump’s drug pricing agenda. ... The drug gained US approval last year, and has just gained marketing clearance in the EU.

Latest news

  • Drug pricing is pharma’s top concern in 2019 Drug pricing is pharma’s top concern in 2019

    Drug pricing and reimbursement remains at the forefront of pharma executive minds as 2019 gets underway, according to a new industry survey. ... GlobalData’s poll also find that while Brexit and political uncertainty in the US were big stories in 2018,

  • After December slump, what’s in store for biotech in 2019? After December slump, what’s in store for biotech in 2019?

    the difficulties biotech companies have achieving profitability once their products reach the market, and of course issues such as drug pricing and the sustainability of economic growth.

  • Beneluxa: the future of European market access? Beneluxa: the future of European market access?

    The agencies are also reusing each other’s drug assessment reports in order to cut out unnecessary duplication. ... Meanwhile, there are some major concerns for pharma, too: some stakeholder groups want to use the legislation to enforce complete

  • Better together when buying medicines? Taking stock of the BeNeLuxA initiative Better together when buying medicines? Taking stock of the BeNeLuxA initiative

    Apply that to the fragmented and diverse landscape of drug pricing and reimbursement in Europe and the reality becomes a lot more complicated. ... There is MEDEV too, an informal cooperation on the assessment, pricing and reimbursement of medicines in

  • Vertex rises on data for cystic fibrosis triple therapy Vertex rises on data for cystic fibrosis triple therapy

    Company will wait for further results before filing. Vertex Pharma has unveiled the first phase 3 data from its highly-anticipated three-drug combination for cystic fibrosis (CF), setting up a ... The interim results come from two studies of its two-drug

More from news
Approximately 55 fully matching, plus 174 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    The Health Secretary, Alex Azar, has promised more to come on “fixing” drug pricing and introducing transparency into drug prices, and in the present political climate that can only be good ... Endocyte’s lead clinical product is 177Lu‐PSMA‐617,

  • Trust me, I’m from pharma Trust me, I’m from pharma

    However, controversies around drug pricing – fuelled by the unhelpful interventions of Martin Shkreli as the pin-up boy for big, bad pharma – have undermined progress and reinforced the view that the ... Individual companies are doing their bit too.

  • Patient outcomes in practice: delivering value that transforms lives Patient outcomes in practice: delivering value that transforms lives

    Providers, payers and manufacturers all have a role in achieving value, with increasing ethical pressure on drug pricing and resultant innovative, outcomes-based pricing models.

  • Drug pricing

  • Risky business for pharma Risky business for pharma

    Chan Lee, North America general counsel, Sanofi, explained: “Drug pricing is a significant risk in our industry, particularly in the US.” Lee also cited “scrutiny of manufacturer interactions with payers, patients, ... PD Villareal, senior vice

More from intelligence
Approximately 7 fully matching, plus 29 partially matching documents found.

Latest appointments

  • Pfizer’s Emms takes up ABPI presidency Pfizer’s Emms takes up ABPI presidency

    Emms is no stranger to these issues, having served on the ABPI board and taken part in the negotiations over the future of drug pricing in the UK. ... He has not been afraid to criticise the outcomes of these discussions too, saying in November that the

  • Bayer's Martin Hesse moves to Daiichi Sankyo Europe

    Commenting on the environment in which he starts at Daiichi, Hesse said securing the company's profitability and competitiveness in the light of drug pricing interventions will a major challenge.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Pricing's Point Man

    In the wake of the publication of the second edition of 'The Price of Global Health', Ed Schoonveld talks to William Looney. Pharm Exec Editor-in-Chief William Looney talks to Ed Schoonveld about the key policy and management issues around market

  • Turkey: Identifying the Growth Drivers

    This sector is dominated by pro-innovative drug prescribing physicians as well as a patient population who is willing to pay for a higher “quality” healthcare. ... Overall, while the public sector is characterised today byaggressive drug pricing

  • Article: The Colombia Conundrum

    drug pricing, as well as a streamlining of the essential drug list to remove some of the higher cost drugs. In a move to combat corruption, the EPS are set to ... This is exemplified by Sanofi’s 2012 acquisition of Genfar, which has resulted in the

  • Ed Schoonveld - new article

    Following the publication of the new edition of The Price of Global Health, Ed Schoonveld writes about the industry's need for new drug pricing model. ... Does the drug industry need a new pricing model? Read Ed Schoonveld's article here  . The new

  • New Schoonveld Book now out!

    Written by global drug pricing expert Ed Schoonveld, The Price of Global Health, second edition, is the most comprehensive book on global pharmaceutical pricing available today. ... The book offers a thorough and straightforward exploration of the drug

More from PMHub
Approximately 3 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics